Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals has convened its 2025 annual general meeting for April 16, 2026 in Shanghai, where shareholders will review the 2025 board work report and annual report, decide on the profit distribution plan, and authorize the board to set an interim dividend plan for 2026. Investors will also vote on auditor re-appointment, director and senior management remuneration, liability insurance for leadership, and a broad share issuance mandate empowering the board to issue up to 20% of existing share capital, including H shares and convertible instruments, providing financial flexibility but potential dilution for shareholders.
The proposed general mandate would allow the board to structure and execute various equity and equity-linked offerings subject to market conditions, including pricing, timing, target investors, and use of proceeds. This expanded discretion over capital-raising tools, along with approvals on compensation and insurance, underscores the company’s efforts to strengthen governance, manage risk for its leadership, and maintain funding optionality as it pursues ongoing growth and strategic initiatives.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative and generic medicines. Listed in Hong Kong as a Class H share issuer, it targets both domestic and international markets with a portfolio spanning oncology, cardiovascular, and other therapeutic areas.
Average Trading Volume: 2,600,925
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$403B
For an in-depth examination of 1276 stock, go to TipRanks’ Overview page.